Three recent Phase III studies have addressed SRS without WBRT as initial treatment for highly selected patients with newly diagnosed brain metastases, demonstrating noninferior survival ...

"WBRT, considered standard of care, is associated with low response rates of about 10% and median survival between 3 and 6 months," Dr Schadendorf explained, adding that systemic treatments such ...